Fundraising FoxLongitude Capital — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.
BiotechPalo Alto, US
James Li(Executive Officer, Director)Maria Fardis(Executive Officer, Director)in
BoardAnna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)Jill Carroll(Director)in
Co-investorsFrazier Life SciencesOrbiMedSR One Capital Management
Infinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants.
BiotechDigital HealthFemTechHealthtechMedical DevicesWellness & FitnessSacramento, US
David J. Kyle(Executive Officer, Director)inJ. Bruce German(Co-founder)David Mills(Founder)inCarlito Lebrilla(Founder)Daniela Barile(Founder)Samara Freeman(Founder & Executive Director, Regulatory Affairs & Intellectual Property)in
Co-investorsAcre Venture PartnersBow CapitalHorizons VenturesiSelect FundSpruce Capital PartnersXeraya Capital+1 more
Ventaris Surgical develops investigational medical devices that are currently under development and have not yet received FDA or other regulatory approval for commercial use.
BiotechHealthtechMedical DevicesSan Carlos, US
Surag Mantri(Executive Officer, Director)
BoardJustin Klein(Director)inMatthew Sprinkel(Director)Amir Abolfathi(Director)Varun Gupta(Director)in
Co-investorsBoutique Venture PartnersNeotribe VenturesSCP Ventures, LLCVensana Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.